Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.

Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.

Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.

At MorphoSys AG, he served as vice president and head of clinical development, leading clinical strategy for hematology and oncology programs including monoclonal antibody therapeutics targeting CD19, CD38, and PSMA.

Heeger holds an MD and Master of Healthcare Management from the University of Heidelberg in Germany. He completed clinical oncology training at University Hospital Heidelberg and the German Cancer Research Center.

The appointment comes as Actinium prepares for data readouts and expanded clinical trials for its pipeline including Actimab-A, ATNM-400, and Iomab-ACT in the second half of 2026.

Actinium develops targeted radiotherapies for cancer treatment, focusing on solid tumors and hematologic malignancies. The company's pipeline includes ATNM-400 for prostate, lung and breast cancers, and Actimab-A for acute myeloid leukemia and myelodysplastic syndrome.